← All trials
NCT05044117
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2021
- Primary completion
- Oct 31, 2026
- Completion date
- Oct 31, 2026
- First posted
- Sep 14, 2021
- Last posted
- Oct 25, 2021
- Enrollment
- 220
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Fujian Medical UniversityCollaborator
- Sun Yat-Sen UniversityReponsible party - principal investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Jiangmen Central HospitalCollaborator
- Guangzhou Panyu Central HospitalCollaborator
- Hanzhong Central HospitalCollaborator
- Guangdong Medical UniversityCollaborator
- People's Hospital Of YichangCollaborator
- The First People's Hospital of HuaihuaCollaborator
- The Central Hospital of YongzhouCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.